Idiopathic Pulmonary Comorbidities and Mechanisms
Idiopathic pulmonary fibrosis (IPF) is a disease with an unknown etiology mainly characterized by a progressive decline of lung function due to the scarring of the tissue deep in the lungs. The overall survival after diagnosis remains low between 3 and 5 years. IPF is a heterogeneous disease and muc...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-01-01
|
| Series: | International Journal of Inflammation |
| Online Access: | http://dx.doi.org/10.1155/2021/3963659 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850220018094047232 |
|---|---|
| author | Maricica Pacurari Amal Mitra Timothy Turner |
| author_facet | Maricica Pacurari Amal Mitra Timothy Turner |
| author_sort | Maricica Pacurari |
| collection | DOAJ |
| description | Idiopathic pulmonary fibrosis (IPF) is a disease with an unknown etiology mainly characterized by a progressive decline of lung function due to the scarring of the tissue deep in the lungs. The overall survival after diagnosis remains low between 3 and 5 years. IPF is a heterogeneous disease and much progress has been made in the past decade in understanding the disease mechanisms that contributed to the development of two new drugs, pirfenidone and nintedanib, which improved the therapeutic management of the disease. The understanding of the cofactors and comorbidities of IPF also contributed to improved management of the disease outcome. In the present review, we evaluate scientific evidence which indicates IPF as a risk factor for other diseases based on the complexity of molecular and cellular mechanisms involved in the disease development and of comorbidities. We conclude from the existing literature that while much progress has been made in understating the mechanisms involved in IPF development, further studies are still necessary to fully understand IPF pathogenesis which will contribute to the identification of novel therapeutic targets for IPF management as well as other diseases for which IPF is a major risk factor. |
| format | Article |
| id | doaj-art-7d16a2dbe3d44e10879544251d002789 |
| institution | OA Journals |
| issn | 2090-8040 2042-0099 |
| language | English |
| publishDate | 2021-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Inflammation |
| spelling | doaj-art-7d16a2dbe3d44e10879544251d0027892025-08-20T02:07:12ZengWileyInternational Journal of Inflammation2090-80402042-00992021-01-01202110.1155/2021/39636593963659Idiopathic Pulmonary Comorbidities and MechanismsMaricica Pacurari0Amal Mitra1Timothy Turner2Department of Biology, College of Science, Engineering, and Technology, Jackson State University, Jackson, MS 39217, USADepartment of Epidemiology and Biostatistics, School of Public Health, Jackson State University, Jackson, MS 39217, USADepartment of Biology, College of Science, Engineering, and Technology, Jackson State University, Jackson, MS 39217, USAIdiopathic pulmonary fibrosis (IPF) is a disease with an unknown etiology mainly characterized by a progressive decline of lung function due to the scarring of the tissue deep in the lungs. The overall survival after diagnosis remains low between 3 and 5 years. IPF is a heterogeneous disease and much progress has been made in the past decade in understanding the disease mechanisms that contributed to the development of two new drugs, pirfenidone and nintedanib, which improved the therapeutic management of the disease. The understanding of the cofactors and comorbidities of IPF also contributed to improved management of the disease outcome. In the present review, we evaluate scientific evidence which indicates IPF as a risk factor for other diseases based on the complexity of molecular and cellular mechanisms involved in the disease development and of comorbidities. We conclude from the existing literature that while much progress has been made in understating the mechanisms involved in IPF development, further studies are still necessary to fully understand IPF pathogenesis which will contribute to the identification of novel therapeutic targets for IPF management as well as other diseases for which IPF is a major risk factor.http://dx.doi.org/10.1155/2021/3963659 |
| spellingShingle | Maricica Pacurari Amal Mitra Timothy Turner Idiopathic Pulmonary Comorbidities and Mechanisms International Journal of Inflammation |
| title | Idiopathic Pulmonary Comorbidities and Mechanisms |
| title_full | Idiopathic Pulmonary Comorbidities and Mechanisms |
| title_fullStr | Idiopathic Pulmonary Comorbidities and Mechanisms |
| title_full_unstemmed | Idiopathic Pulmonary Comorbidities and Mechanisms |
| title_short | Idiopathic Pulmonary Comorbidities and Mechanisms |
| title_sort | idiopathic pulmonary comorbidities and mechanisms |
| url | http://dx.doi.org/10.1155/2021/3963659 |
| work_keys_str_mv | AT maricicapacurari idiopathicpulmonarycomorbiditiesandmechanisms AT amalmitra idiopathicpulmonarycomorbiditiesandmechanisms AT timothyturner idiopathicpulmonarycomorbiditiesandmechanisms |